The incidence and the demographic and clinical characteristics of patients with inflammatory bowel disease in our region

Yıl 2019, Cilt: 18 Sayı: 2, 49 - 58, 15.09.2019

Özlem Özer Çakır

https://doi.org/10.17941/agd.521248

Cited By: 1

Öz

Background
and Aims: This study was
conducted to evaluate the clinical and demographic characteristics of patients
diagnosed with inflammatory bowel disease who were followed up and treated in
our tertiary care hospital for the past 1 year and to determine the annual
incidence and prevalence according to the population. Material and Methods: This
retrospective study recorded and analyzed the clinical and demographic data of
patients with inflammatory bowel disease who applied to Alanya Alaaddin
Keykubat University Alanya Training and Research Hospital between July 2017 and July 2018. Results: A total of 111 patients (53 patients with ulcerative
colitis, 48 patients with Crohn’s disease, and 10 patients with indeterminate
colitis) were included in this study. No significant
difference was detected between the mean age and the gender distribution among
patients with ulcerative colitis, Crohn’s disease,[Author1] 
and indeterminate colitis. Ulcerative
colitis (50.9%) and indeterminate colitis (70%) were more frequent among males, whereas Crohn’s
disease (52.1%) was more frequent among females. Conclusions: In terms of the distribution according to age, ulcerative colitis showed the maximum
prevalence of 60% in
our region among patients in the age range of 40–[Author2] 49
years, whereas Crohn’s disease exhibited a bimodal
peak, with prevalence rates of 53.8% in the 19–[Author3] 29-year age group and 57.1% in
the age group of >60 years. The
incidence rates for ulcerative colitis, Crohn’s disease,
and indeterminate colitis were 3.67, 7.34, and 1.33 per 100 000 people, respectively.

Anahtar Kelimeler

Ulcerative colitis, Crohn’s disease, Alanya, epidemiyoloji

Bölgemizdeki inflamatuar barsak hastalıkları tanılı olguların insidansı, demografik ve klinik özellikleri

Öz

Giriş ve Amaç:
Bu çalışmada üçüncü basamak hastanemizde son bir yıldır inflamatuvar barsak
hastalıkları tanısı ile takip ve tedavi edilen hastaların klinik ve demografik
özelliklerinin incelenmesi ve nüfusa göre yıllık insidans ve prevalansının
belirlenmesi amaçlandı. Gereç ve Yöntem:
Bu retrospektif çalışmada, Temmuz 2017 ile Temmuz 2018 arasında Alanya Alaaddin
Keykubat Üniversitesi Alanya Eğitim ve Araştırma Hastanesi’ne başvuran
inflamatuvar barsak hastalığı tanılı hastaların klinik ve demografik bilgileri
kayıt edildi. Bulgular: Çalışmaya
111 hasta (53’ü ülseratif kolit, 48’i Crohn hastalığı, 10’u indetermine kolit)
dahil edildi. Ülseratif kolit, Crohn hastalığı ve indetermine kolit hastalarında
ortalama yaş ve cinsiyet dağılımları anlamlı farklılık göstermedi. Ülseratif kolit hastalığı %50.9 ile
erkek cinsiyette daha sık görülürken, Crohn hastalığı %52.1 ile kadın
cinsiyette ve indetermine kolit ise %70 ile erkek cinsiyette daha sık
görülmekte idi. Sonuç: Yaşlara göre dağılımlara bakıldığında,
bölgemizde ülseratif kolit  40-49 yaş
aralığında %60 ile en sık görülürken, Crohn hastalığının ise 19-29 yaş
aralığında %53.8 ve ≥60 yaşta %57.1 olmak üzere bimodal
pik yaptığını izledik. Ülseratif kolit için insidans her 100 000’de
3.67 iken, Crohn hastalığı için her 100 000’de 7.34 olup, indetermine kolit
için ise her 100 000’de 1.33 olarak tespit edilmiştir.

Anahtar Kelimeler

Ülseratif kolit, Crohn hastalığı, Epidemiyoloji

Kaynakça

• Kaynaklar1. Pierik M, Yang H, Barmada MM, et al. The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. Inflamm Bowel Dis. 2005;11:1–7.2. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–62. 3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17 4. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Infl amm Bowel Dis 2006; 12 (Suppl 1): S3–S9.5. Loftus EV Jr, Sandborn WJ. Epidemiology of infl ammatory bowel disease. Gastroenterol. Clin. North Am 2002; 31: 1–20. 6. M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33–47. 7. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018 Dec 23;390(10114):2769-78.8. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015 Aug;50(8):942-51.9. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82–6.10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–29.11. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's Disease Activity Index. National Co-operative Crohn's disease study. Gastroenterology. 1976;70:439–44.12. Tezel A, Dökmeci G, Eskiocak M, et al. Epidemiological features of ulcerative colitis in Trakya, Turkey. J Int Med Res 2003;31:141-8.13. Tozun N, Atug O, Imeryuz N, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol 2009;43:51-7.14. Shivashankar R, Tremaine WJ, Harmsen WS, et al. Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol. 2017 Jun;15(6):857-63.15. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–9. 16. Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43:S85–93. 17. Abdul-Baki H, ElHajj I, El-Zahabi LM, et al. Clinical epidemiology of inflammatory bowel disease in Lebanon. Inflamm Bowel Dis. 2007;13:475–80. 18. Niv Y, Abuksis G, Fraser GM. Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol. 2000;95:693–819. Al-Shamali MA, Kalaoui M, Patty I, et al. Ulcerative colitis in Kuwait: a review of 90 cases. Digestion. 2003;67:218–24. 20. Vahedi H, Merat S, Momtahen S, et al. Epidemiologic characteristics of 500 patients with inflammatory bowel disease in Iran studied from 2004 through 2007.Arch Iran Med. 2009;12:454–60. 21. Aghazadeh R, Zali MR, Bahari A, et al. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol. 2005;20:1691–5. 22. Balram C, Sharma A, Sivathasan C, Lee EJ. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003;56:78–83. 23. Fallahi GH, Moazzami K, Tabatabaeiyan M, et al. Clinical characteristics of Iranian pediatric patients with inflammatory bowel disease. Acta Gastroenterol Belg. 2009;72:230–4. 24. Masjedi zadeh R, Hajiani E, Hashemi SJ, et al. Epidemiological features of inflammatory bowel disease in Khozestan. Jundishapur Sci Med J. 2007;6:54–63. Persian. 25. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis. 2004;10:646–51.26. Ozin Y, Kilic MZ, Nadir I, et al. Clinical features of ulcerative colitis and Crohn's disease in Turkey. J Gastrointestin Liver Dis 2009;18:157-62.27. Ülker A, Parlak E, Dağlı Ü. et al. Epidemiology of ınfl ammatory bowel disease. Türk J Gastroenterol 1999; 10: 55 – 9. 28. Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis. 2008;14 (Suppl 2):S14-S5.29. Reif S, Lavy A, Keter D, et al. Lack of association between smoking and Crohn’s disease but the usual association with ulcerative colitis in Jewish patients in Israel: a multicenter study. Am J Gastroenterol. 2000;95:474–8.